ArticleLancet (London, England)2019
Pembrolizumab for all PD-L1-positive NSCLC.
Article in Lancet (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Toll-like receptor 3 activation enhances antitumor immune response in lung adenocarcinoma through NF-κB signaling pathway.Frontiers in immunology · 2025Article
- Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.Oncoimmunology · 2024Article
- Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials.Journal of the National Cancer Institute · 2023Article
- Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments.Immuno-oncology technology · 2022Article
- A Problematic Biomarker Trial Design.Journal of the National Cancer Institute · 2022Article
- Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study.Frontiers in oncology · 2021Article
- ctDNA facilitated the diagnosis of a patient with synchronous urothelial carcinoma and non-small cell lung cancer: case report.Annals of translational medicine · 2020Article
- Review
- Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?Translational cancer research · 2019Article
- The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?Translational lung cancer research · 2019Article
- EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCAREJournal of Cancer · 2019Article
- Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.Frontiers in immunology · 2019Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30955976What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.